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ABSTRACT
L-nucleoside analogs represent an important class
of small molecules for treating both viral infections
and cancers. These pro-drugs achieve pharmaco-
logical activity only after enzyme-catalyzed conver-
sion to their tri-phosphorylated forms. Herein, we
report the crystal structures of human deoxycyti-
dine kinase (dCK) in complex with the L-nucleosides
(-)-b-20,30-dideoxy-30-thiacytidine (3TC)—an appro-
ved anti-human immunodeficiency virus (HIV)
agent—and troxacitabine (TRO)—an experimental
anti-neoplastic agent. The first step in activating
these agents is catalyzed by dCK. Our studies reveal
how dCK, which normally catalyzes phosphory-
lation of the natural D-nucleosides, can efficiently
phosphorylate substrates with non-physiologic
chirality. The capability of dCK to phosphorylate
both D- and L-nucleosides and nucleoside analogs
derives from structural properties of both the
enzyme and the substrates themselves. First, the
nucleoside-binding site tolerates substrates with
different chiral configurations by maintaining virtu-
ally all of the protein-ligand interactions responsible
for productive substrate positioning. Second, the
pseudo-symmetry of nucleosides and nucleoside
analogs in combination with their conformational
flexibility allows the L- and D-enantiomeric forms to
adopt similar shapes when bound to the enzyme.
This is the first analysis of the structural basis for
activation of L-nucleoside analogs, providing further
impetus for discovery and clinical development of
new agents in this molecular class.
INTRODUCTION
Chirality is a hallmark of biological systems: proteins are
composed of L-amino acids and DNA and RNA are com-
posed of b-D-nucleotides. It has, therefore, been widely
accepted that enzymes that must correctly bind ligands and
catalyze chemistry on their respective substrates, will invari-
ably show high chiral selectivity. Quite unexpectedly,
however, it was demonstrated that it is the L-component
of the racemic mixture (±)-BCH-189 [(±)-b-20,30-dideoxy-
30-thiacytidine], which possesses signiﬁcantly better anti-
human immunodeﬁciency virus (HIV) properties than its
D-enantiomeric counterpart (1,2). Since this discovery, two
non-physiologic L-nucleoside analogs [(-)-b-20,30-dideoxy-
30-thiacytidine (3TC), the L-enantiomer of BCH-189, and
its 5-ﬂuorinated analog FTC] have been approved for treat-
ment of human acquired immune deﬁciency syndrome
(AIDS). An additional six D-nucleoside analogs have been
approved as AIDS therapeutics, and it is customary for
patients to receive both L- and D-enantiomer anti-HIV
agents simultaneously. The pharmacological potential of
L-nucleoside analogs has been recently reviewed (3–5). The
dioxolane analog of 3TC, troxacitabine [TRO, (-)-L-b-20,
30-dideoxy-30-oxacytidine; Figure 1A] is currently in a Phase
II/III clinical trial for third-line treatment of acute myeloge-
nous leukemia (AML), a blood cancer. The L-nucleoside
analogs 3TC and FTC are preferred as anti-virals over their
D-analogs [(+)-BCH-189 and (+)-FTC, respectively], primar-
ily because these HIV reverse transcriptase inhibitors do not
affect cellular DNA polymerases (4), resulting in minimal
toxicity. In contrast, TRO, the ﬁrst L-nucleoside analog to
be used as a cytotoxic anti-cancer agent (6), which differs
from 3TC by only one atom (S versus O in the ﬁve membered
ring, Figure 1A), has potent anti-viral activity yet displays
substantial cellular toxicity due to inhibition of DNA poly-
merases a, b and g (7). Unlike the D-nucleoside analog
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doi:10.1093/nar/gkl1038anti-cancer agent cytarabine (AraC), TRO is not a substrate
for the drug-modifying enzyme cytidine deaminase (6) that
confers cytarabine resistance in AML (8).
Metabolic conversion of 3TC and TRO to pharmacologi-
cally active drugs requires serial phosphorylation to their
triphosphorylated forms. The essential ﬁrst step in this process
is catalyzed by deoxycytidine kinase (dCK) (6,9–11), which
together with the two mitochondrial enzymes thymidine
kinase (TK2) and deoxyguanosine kinase (dGK), constitute a
family of three closely related non-enantioselective enzymes
responsible for nucleoside phosphorylation (12,13). Lack of
selectivity pertains to both substrates and enantiomers. dCK
phosphorylates dC, dA and dG. TK2 phosphorylates both dC
and deoxythymidine (dT), and dGK phosphorylates both dA
and dG. The overlapping substrate speciﬁcity of these nucleo-
side kinases reﬂects their differing sub-cellular localization:
dCK is cytosolic, whereas TK2 and dGK are mitochondrial.
All three enzymes are capable of phosphorylating both
L- and D-enantiomers (14–16).
The question that we set out to answer is what structural
features endow certain enzymes, such as dCK, the ability to
accept substrates with non-physiological chirality? Answer-
ing this question is signiﬁcant not only for our understanding
of enzyme speciﬁcity, but also has medicinal ramiﬁcations
as more L-nucleoside analogs enter clinical trials. To address
this issue, we solved the crystal structures of human dCK
in complex with the two clinically relevant L-nucleoside
analogs, 3TC and TRO. This is the ﬁrst report of an enzyme
in complex with an L-nucleoside.
MATERIALS AND METHODS
Protein crystal preparation
Initial attempts to crystallize wild-type dCK with 3TC and
TRO were hampered by reproducibility. Modiﬁcation of all
four surface-exposed cysteine residues yielded a signiﬁcantly
better behaved crystallization candidate, thereby making
this study feasible. The dCK variant containing the C9S/
C45S/C59S/C146S mutations, designated C4S-dCK, was cre-
ated from the wild-type dCK gene, using QuickChange 
(Stratagene, Inc.). The protein was produced in Escherichia
coli and puriﬁed to homogeneity (E. Sabini, S. Hazra,
M. Konrad and A. Lavie, manuscript in preparation) In
short, E.coli BL21(DE3) harboring the pET14b expression
plasmids were grown in 2YT media at 37 C, induced with
0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and
harvested by centrifugation after 4 h. After lysis by sonica-
tion and ultracentrifugation, the supernatant was loaded onto
a HisTrap HP Ni Sepharose column (GE Healthcare) and
washed with buffer containing 50 mM HEPES (pH 7.5),
500 mM NaCl and 20 mM imidazole. The enzyme was
Figure 1. (A) Schematic of the D- and L-nucleosides (all in b-form): 3TC, ( )-L-20,30-dideoxy-30-thiacytidine (Lamivudine, Epivir ); TRO, ( )-L-20,
30-dideoxy-30-oxacytidine (Troxacitabine, Troxatyl ); D-dC, D-20-deoxycytidine, and L-dC, L-20-deoxycytidine. Experimental electron density map for the
L-nucleoside analogs: (B) 3TC is shown in yellow and (C) TRO in magenta. The difference map (|Fobs|   |Fcalc|) is contoured at 3s (light blue) and 8s (orange).
Note the strong signal given by the sulfur atom in 3TC even at the high sigma cut-off. Figures were generated using Bobscript (26) and Molscript (27), and
rendered with Raster3D (28).
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imidazole. After protein concentration by centrifugation, the
protein was injected onto a S-200 gel ﬁltration column (GE
Healthcare) equilibrated with 20 mM HEPES (pH 7.5),
200 mM sodium citrate and 2 mM EDTA. The fractions
containing the enzyme were concentrated to  20 mg/ml
and stored at  80 C.
Ternary complexes were formed by mixing each nucleo-
side analog (3TC, obtained from the NIH AIDS Research
and Reference Reagent Program, Division of AIDS; TRO,
provided by SGX Pharmaceuticals, Inc.) with adenosine
diphosphate (ADP) (ﬁnal concentrations 5 mM each) and
enzyme (10–20 mg/ml) in 5 mM MgCl2. Crystals were obtai-
ned under identical conditions as for wild-type dCK (17) via
hanging drop vapor diffusion against a reservoir containing
0.95–1.5 M sodium citrate and 100 mM HEPES (pH 7.5).
Data collection and processing
X-ray data were obtained under standard cryogenic condi-
tions at the Advanced Photon Source using SERCAT beamline
BM-22. Diffraction data were indexed, scaled and merged
using XDS and XSCALE (18) (see Table 1 for data collection
statistics).
Structure determination and refinement
Ternary complex structures were determined via molecular
replacement [MOLREP (19)] using the structure of wild-
type dCK-D-dC/ADP (17) [PDB Code: 1P60 (20)] as the
search model. Reﬁnement was carried out using REFMAC
(21) and simulated annealing maps were calculated using
CNS (22) (see Table 1 for reﬁnement statistics).
Steady-state kinetic assay
A spectroscopic enzyme-coupled assay was used to determine
enzyme activity as described previously (23). This assay cou-
ples the production of ADP or UDP by dCK to the phospho-
rylation of phosphoenolpyruvate (PEP) by pyruvate kinase,
followed by oxidation of NADH by lactate dehydrogenase.
The decrease in NADH absorption is proportional to the
ADP/UDP produced by dCK. The extinction coefﬁcient of
NADH limits the precise measurement of Km values below
 3 mM. For this reason, substrates displaying a Km value
below 3 mM are reported in Table 2 to this higher limit.
The measurement of kcat values is unaffected by this technical
limitation of the assay. Experiments were conducted at 37 C
in a kinetic buffer containing 50 mM Tris–HCl (pH 7.5),
100 mM KCl and 5 mM MgCl2 with dCK: 0.35 mM, adeno-
sine triphosphate (ATP)-Mg: 1 mM and uridine triphosphate
(UTP)-Mg: 1 mM. Nucleoside/nucleoside analog concentra-
tions were varied between 5 and 100 mM.
Validation of choice of crystallization protein
To verify that the Cys!Ser mutations in C4S-dCK did not
perturb the structure, ternary complex crystals of the C4S
Table 1. Data collection and refinement statistics
Human C4S-dCK
3TC-ADP TRO-ADP
PDB ID 2NOA 2NO9
Beamline SERCAT BM-22 SERCAT BM-22
Wavelength (A ˚) 1.0 1.0
Temperature (K) 100 100
Resolution (A ˚) 1.8 2.15
(1.8–1.9) (2.15–2.20)
Reflections
Observed 156829 156130
Unique 50033 30536
Completeness (%) 95.3 (74.8) 99.7 (100.0)
Rsym(%) 5.9 (43.5) 9.9 (51.1)
I/s(I) 12.0 (2.3) 10.9 (4.4)
Space group C2221 C2221
Unit cell (A ˚)
a 52.6 52.9
b 134.2 134.5
c 154.9 155.3
Molecules per a.u. 2 2
Refinement statistics
Rcryst (%) 19.2 19.5
Rfree (%) 23.3 25.5
Resolution range (A ˚) 30–1.8 30–2.15
Number of atoms
Protein 2014 (chain A) 1978 (A)
1842 (chain B) 1872 (B)
Nucleoside 15 · 21 5 · 2
ADP 27 · 22 7 · 2
Water 197 79
R.m.s. deviation
Bond length (A ˚) 0.015 0.016
Bond angles ( ) 1.665 1.718
Average B-factors (A ˚ 2)
Protein 26 (A) 36 (A)
28 (B) 38 (B)
Main chain 25 (A) 35 (A)
27 (B) 37 (B)
Side chain 27 (A) 37 (A)
29 (B) 39 (B)
ADP 19 (A) 29 (A)
21 (B) 28 (B)
Nucleoside 20 (A) 28 (A)
24 (B) 32 (B)
Waters 32 38
Table 2. Steady state kinetic data of WT and C4S-dCK
a
Enzyme-substrate Km (ATP) mM Km (UTP) mM kcat (ATP) s
 1 kcat (UTP) s
 1 kcat/Km (ATP) s
 1M
 1 kcat/Km (UTP) s
 1M
 1
WT-TRO 13.2 ± 0.8 10.6 ± 1.3 0.095 ± 0.002 0.179 ± 0.006 7.2 · 10
3 16.9 · 10
3
C4S-TRO 56.8 ± 3.0 57.8 ± 7.9 0.192 ± 0.004 0.524 ± 0.030 3.4 · 10
3 9.1 · 10
3
WT-3TC 3.4 ± 1.0 8.0 ± 1.0 0.030 ± 0.001 0.102 ± 0.001 8.8 · 10
3 12.8 · 10
3
C4S-3TC 8.4 ± 1.4 14.9 ± 1.3 0.028 ± 0.002 0.072 ± 0.002 3.3 · 10
3 4.8 · 10
3
WT-L-dC <3 <3 0.012 ± 0.001 0.010 ± 0.001 >4 · 10
3 >3 · 10
3
C4S-L-dC <3 <3 0.036 ± 0.001 0.042 ± 0.001 >12 · 10
3 >14 · 10
3
WT-D-dC <3 <3 0.033 ± 0.001 0.049 ± 0.001 >11 · 10
3 >16 · 10
3
C4S-D-Dc 3.0 ± 0.2 <3 0.173 ± 0.002 0.217 ± 0.005 57.7 · 10
3 >72 · 10
3
aValues shown are the averages of at least two experiments and SDs are shown.
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2NO1) and gemcitabine/ADP (PDB ID 2NO0) and compared
to structures previously determined with wild-type enzyme
(17). These control complexes crystallized in the same
space group as the L-nucleoside complexes, and diffracted
to 1.9 (D-dC/ADP complex) and 1.8 s (gemcitabine/ADP)
resolution (E. Sabini, S. Hazra, M. Konrad and A. Lavie,
unpublished data). No signiﬁcant structural differences were
noted between corresponding polypeptide chain structures
[root mean square deviation (r.m.s.d.) between 241 a carbon
atomic positions: wild-type dCK-D-dC/ADP versus C4S-
dCK-D-dC/ADP ¼ 0.16 s; dCK-gemcitabine/ADP versus
C4S-dCK-gemcitabine/ADP ¼ 0.60 s] or substrate positions.
Finally, no signiﬁcant differences in catalytic efﬁciency were
observed between wild-type and C4S-dCK for two distinct
phosphate donors and multiple acceptors (Table 2). Together,
these control experiments validate the use of the C4S mutant
for structure determination. When referring to structures of
dCK herein, we make no distinction between wild type and
the C4S mutant, unless otherwise stated.
RESULTS AND DISCUSSION
The ternary complex structures of dCK-3TC/ADP and dCK-
TRO/ADP were determined at 1.8 and 2.15 s resolution,
respectively. Excellent difference electron density maps
were observed for the L-nucleoside analogs (Figure 1B and
C). After several rounds of model building and reﬁnement,
in which the nucleotide ADP and the respective L-nucleoside
analogs were modeled into the density, and addition of water
molecules, the ﬁnal crystallographic R-factors (Rfrees) con-
verged to 19.2% (23.3%) and 19.5% (25.5%) for the 3TC
and TRO complexes, respectively (Table 1).
When compared to the ternary complex structures of dCK-
D-dC/ADP and dCK-L-dC/ADP (E. Sabini, S. Hazra,
M. Konrad and A. Lavie, unpublished data), binding of these
L-nucleoside analogs does not affect the structure of the
polypeptide chain r.m.s.d. for 239 common a-carbon atoms
among pairs of ternary complex structures ¼ 0.18–0.30 s]
nor the positions of the ADP molecules (Figure 2A). In
contrast, the mode of L-nucleoside/L-nucleoside analog
binding differs from that of D-nucleosides (Figure 2B
and C).
The active site environment surrounding each L-nucleoside
analog is shown in Figure 3A, accompanied by similar views
for dCK-D-dC/ADP and dCK-L-dC/ADP (Figure 3B). D-dC is
the mirror image of L-dC (chirality being determined by the
location of the CH2OH group at the C40 chiral centre or
ribose 40 position, Figures 1A and 3B). 3TC and TRO closely
resemble one another, and only differ from L-dC at the 30
position (Figure 1A). All three L-nucleosides bind similarly
to dCK. Detailed comparison of the protein–ligand interac-
tions, presented schematically in Figure 4, reveals the struc-
tural basis for non-enantioselective phosphorylation by
dCK. For both 3TC and TRO, the enzyme satisﬁes the
same requirements for substrate recognition/catalysis that
govern phosphorylation of its primary physiologic substrate,
D-dC. First, hydrogen bonding interactions between the pro-
tein and the ligand permit the protein to detect the presence
of a hydrogen bond donor (NH2) and two hydrogen bond
acceptors (N; O) characteristic of the cytosine base
Figure 2. Structures of dCK-3TC/TRO complexes. (A) Shown are four
superimposed structures of human dCK: the C4S variant in complex with
3TC/ADP (yellow), TRO/ADP (magenta) and D-dC/ADP (blue); the WT in
complex with D-dC/ADP (gray; PDB ID 1P5Z). The structures in complex
with D-dC/ADP of the dCK C4S variant and the WT dCK are basically
identical, apart from one loop involved in crystal contact. This validates
the use of the C4S mutant as a representative of WT dCK. Binding of
L-nucleosides also does not elicit major structural perturbations. Non-carbon
atom color coding: oxygen-red, nitrogen-blue, phosphorous-green and sulfur-
orange. The N- and C-terminal residues visible in the experimental electron
density map are labeled N20 and C260, respectively. (B) Stereo representation
of the active site showing hydrogen bonding interactions (some water
molecules omitted, for clarity). Curved arrow signifies the c torsion angle
around the glycosidic bond. (C) Stereo representation of the active site in an
orientation rotated  90  relative to (B) depicting the cytosine base in the
aromatic slot with Leu82 and Ile30 sandwiching the sugar. Structures have
been deposited in the PDB with accession ID 2NOA for C4S-3TC/ADP,
2NO9 for C4S-TRO/ADP and 2NO1 for C4S-D-dC/ADP.
Nucleic Acids Research, 2007, Vol. 35, No. 1 189(Figure 2B). Second, the ﬁve-membered ring resembling the
ribose is positioned so as to place the site of phosphorylation
(50-OH) in the appropriate location for phosphoryl transfer
from ATP.
Despite the difference in chirality between the physiologic
substrate D-dC and the L-nucleoside analogs 3TC/TRO, the
location of the cytosine base and its interactions with the
enzyme are comparable. In all three ternary complex struc-
tures depicted in Figure 2B, Asp133 forms hydrogen bonds
with the cytosine amino group. However, it is Gln97 that
serves as the primary cytosine recognition element contribut-
ing two hydrogen bonds between its side chain and the com-
ponents of the base that normally engage in Watson–Crick
type hydrogen bonding with guanosine (Gln97 O!NH2;
Gln97 NH2!N; Figures 2B and 4A). The fourth hydrogen
bonding interaction between the protein and the base appears
as a water bridge (Tyr204/Tyr86!H2O!O; Figures 2B and
4A). Analogous interactions with comparable hydrogen bond
geometries occur between dCK and the cytosine bases of
D-dC and L-dC (data not shown). The base itself sits deep
in an aromatic slot, which is lined by the side chains of
Phe137, Phe96 and Trp58 (all conserved among dCK, dGK
and TK2). The aromatic cytosine base is pinioned between
Phe137 and Phe96/Trp58. On one face, Phe137 engages in
p–p stacking against the cytosine base (interplanar distance
 3.5 s). On the opposite face, Phe96 and Trp58 both engage
in edge-to-face interactions that place electropositive aro-
matic hydrogen atoms close to the electronegative p-electron
cloud of the cytosine base (Figures 2C and 4B). These
aromatic–aromatic interactions exploit enthalpically favorable
quadrupole–quadrupole interactions characteristic of aromatic
amino acid side chains in proteins as also seen in crystalline
benzene (24). The important systematic difference in the posi-
tion of the cytosine bases of 3TC and TRO versus that of D-dC
is a 10  tilt (Figure 2C). We believe that this difference is a
general feature of L-enantiomers, as the same base tilt is repro-
duced in the structure of L-dC bound to dCK (E. Sabini,
S. Hazra, M. Konrad and A. Lavie, unpublished data).
Figure 3. Interactions activating the 50-OH of the nucleosides for
nucleophilic attack. (A) Stereoview depicting the interactions made by the
50-OH groups of 3TC (yellow) and TRO (magenta). (B) Stereoview depicting
the analogous interactions for D-dC (blue) and L-dC (cyan).
Figure 4. Enzyme-substrate interactions. Schematic representation of the (A) polar and (B) weakly polar and hydrophobic interactions made by 3TC and TRO
with the residues in the dCK active site. Distances (A ˚) are color-coded in (A) with 3TC-yellow and TRO-magenta, while in (B) they are in black and correspond
to the average closest contacts for both structures. Water molecules are represented as cyan balls.
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cytosine base and the aromatic slot, the ﬁve membered
rings of 3TC and TRO make only limited enzyme contacts
(Figures 3A and 4). Critical for catalysis is correct position-
ing of the 50-OH, which receives the transferred phosphate
group from ATP. In the L-nucleoside analog structures
depicted in Figure 3A, the 50-OH group is hydrogen bonded
to the side chain of Arg128. Consequently in each case, the
O50-hydroxyl is close to a side chain oxygen atom of Glu53
(3.1–3.6 s), the general base that activates 50-OH group
attack of the g-phosphate of ATP (see Figures 2B and 3).
To achieve this critical interaction, concomitant with base
tilting, the ﬁve-membered rings of 3TC and TRO rotate
 30  around the glycosidic bond (c, marked with an arrow
in Figure 2B) relative to the dCK-bound conformation of
D-dC. A comparable c rotation observed in the L-dC structure
(E. Sabini, S. Hazra, M. Konrad and A. Lavie, unpublished
data) provides additional evidence that our structural ﬁndings
represent the way in which L-nucleosides and L-nucleoside
analogs bind to dCK.
The four structures depicted in Figure 3 document that
positioning of the 50-OH group in the active site of dCK is
independent of chirality. This remarkable property derives
from the internal symmetry and conformational ﬂexibility
(i.e. rotation about the glycosidic torsion angle c) of nucleo-
sides and nucleoside analogs. Once the cytosine base is
docked into the aromatic slot, the paucity of protein–ligand
interactions involving the ﬁve-membered ring and the confor-
mational properties of the nucleoside permit appropriate posi-
tioning of the 50-OH group. Within the aromatic slot, possible
glycosidic bond torsion angles are limited by the hydrophobic
residues Ile30 and Leu82 (Figures 2C and 4). An additional
degree of freedom dictating the precise location of the
hydroxyl is the pucker of the ﬁve-membered ring. For 3TC
and TRO, the ring pucker is equivalent to C30 endo, whereas
for L-dC and D-dC the sugar pucker is C30 exo. This differ-
ence can be attributed in part to the absence of a 30-OH
group on 3TC and on TRO, both of which can act as DNA
chain terminators. Finally, a torsion angle rotation about the
C40 and C50 bond, from gauche in the D-dC structure to trans
in the complex structures of 3TC, TRO and L-dC, direct the
50-OH group towards Glu53. Although these features of 3TC
and TRO conformational ﬂexibility bring the 50-OH group
near to Glu53 (3.1–3.6 s; Figure 3A), they do not stabilize
the very close, so-called catalytic, interactions seen with
L-dC and D-dC (2.4–2.5 s; Figure 3B). However, the fact
that dCK shows similar catalytic efﬁciency towards 3TC/
TRO and L-dC (Table 2) suggests that the slightly sub-
optimal position observed for the 50-OH group in the 3TC/
TRO structures does not impede catalysis.
In conclusion, the structures reported herein document that
dCK phosphorylation of L-nucleosides and L-nucleoside ana-
logs is due to both the nature of the enzyme active site and
the nature of the substrates. We suggest that lack of enan-
tiomeric selectivity may reﬂect the central role dCK plays
in nucleotide salvage, i.e. phosphorylating both the pyrimi-
dine dC and the purines dA and dG within the cytosolic com-
partment. The by-product of such promiscuity appears to be
non-enantioselectivity. Similar arguments can be invoked to
explain why the related enzymes dGK, which phosphorylates
dA and dG, and TK2, which phosphorylates dT and dC,
are not enantioselective. In contrast, human TK1, which is
restricted to D-dT phosphorylation, is exquisitely enantiose-
lective (25). We suggest that enzymes that evolved to
catalyze more than one chemically distinct nucleoside
substrate acquired less restrictive active sites, which in turn
endowed such enzymes with hitherto unexpected catalytic
activities for substrates with non-physiologic chirality.
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